Semaglutide Study Shows Quality-of-Life Improvements in Diabetic Patients With Kidney Disease

Researchers presented findings from the FLOW trial showing that semaglutide, a medication primarily used for diabetes and weight management, improved quality of life measures in patients living with both type 2 diabetes and chronic kidney disease.

The presentation occurred at the 63rd European Renal Association Congress in Glasgow, Scotland, on June 4, 2026.

The FLOW trial examined how semaglutide affected patient outcomes in this population, which faces overlapping health challenges. Chronic kidney disease and type 2 diabetes frequently occur together, with each condition complicating the management of the other.

Researchers assessed multiple dimensions of patient experience beyond standard clinical markers. The study found that participants receiving semaglutide reported measurable improvements in how they felt and functioned day to day.

The findings expand the discussion around semaglutide's effects. While the medication has gained attention for its weight-reducing properties, the trial results suggest its benefits may extend to psychological and functional well-being in patients managing kidney disease alongside diabetes.

Details about the study's design, sample size, specific quality-of-life measures evaluated, and statistical significance were not fully outlined in available information about the presentation.